PharmaMar closes recruitment for the Phase III Neptuno trial with plitidepsin for the treatment of COVID-19

Given the evolution of the pandemic and its impact on the number of applicable patients, the Company has decided to close the study early. Preliminary data suggest a positive trend of plitidepsin versus the control arm. The final data will be published once they are fully analyzed. PharmaMar (MSE:PHM) has announced today that it is closing the Phase III “Neptuno” trial with plitidepsin for the treatment of COVID-19 in hospitalized patients. The Company has made this decision due to the lack of enrollment of patients for the study given the evolution of the pandemic. Despite an insufficient sample of patients, a preliminary analysis suggests a positive trend, demonstrating the drug’s potent activity. PharmaMar will continue to analyze the trial data for a subsequent publication.

The release as fetched from its publisher. pharmamar.com ↗